XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.2
STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended
May 31, 2019
May 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (468,314) $ (409,577)
Adjustments to reconcile net loss to net cash used in operating activities:    
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D. 316,719 264,720
Changes in operating assets and liabilities    
Prepaids 11,715 11,714
Accounts payable (3,867) 23,184
Accrued liabilities 7,932 (6,358)
NET CASH USED IN OPERATING ACTIVITIES (135,815) (116,317)
CASH FLOWS FROM FINANCING ACTIVITIES    
Contribution of capital 138,217 116,017
NET CASH PROVIDED BY FINANCING ACTIVITIES 138,217 116,017
NET INCREASE (DECREASE) IN CASH 2,402 (300)
CASH AT BEGINNING OF PERIOD 708 506
CASH AT END OF PERIOD $ 3,110 $ 206